Stephen F. Betz - 15 Dec 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
15 Dec 2022
Net transactions value
-$50,016
Form type
4
Filing time
19 Dec 2022, 16:11:22 UTC
Previous filing
05 Dec 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale $50,016 -3,126 -3.7% $16.00 82,403 15 Dec 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Includes 561 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022 by the Reporting Person.